Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / BAX - Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing | Benzinga


BAX - Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing | Benzinga

  • Tigris patient enrollment momentum continues reaching 72

    The Company anticipates three additional trial sites to be activated in Q3

    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

    TORONTO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) ("Spectral" or the "Company") is pleased to announce that it has closed its previously announced "bought deal" private placement of 9.0% convertible unsecured senior notes due November 1, 2026 (the "Notes") of the Company at a price of US$1,000 per Note (the "Issue Price") for aggregate gross proceeds of US$4,553,000 (the "Offering"). The Offering was conducted by Paradigm Capital Inc. (the "Underwriter") and consisted of the sale of 4,553 Notes at a price of US$1,000 per Note.

    The Notes have a face value of US$1,000 per Note, bear interest of 9% and are due on November 1, 2026 (the "Maturity Date"). Holders of the Notes may convert all or any portion of the Notes into common shares of the Company (the "Common Shares") in integral multiples of US$1,000 principal amount at any time prior to the Maturity Date. Each Note is convertible into approximately 15,475,647 Common Shares, subject to customary anti-dilution and make whole fundamental change adjustments. Pursuant to the Note Offering, Baxter International Inc. (NYSE:BAX) ("Baxter") agreed to purchase certain of the Notes in connection with an amendment to a portion of the last milestone payment due to the Company under the Distribution Agreement (as defined below). In 2020, Baxter, a leading global medical products company, entered into a distribution agreement (the "Distribution Agreement") with the Company for PMX (as defined below) and the Endotoxin Activity AssayTM (EAA), an on-market companion diagnostic tool that aids in the risk assessment of ICU patients for progression to severe sepsis.

    In connection with the Offering, the Underwriter received a cash commission of US$273,180 and 928,539 compensation options (the "Compensation Options"), with each Compensation Option ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Baxter International Inc.
    Stock Symbol: BAX
    Market: NYSE
    Website: baxter.com

    Menu

    BAX BAX Quote BAX Short BAX News BAX Articles BAX Message Board
    Get BAX Alerts

    News, Short Squeeze, Breakout and More Instantly...